Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection

scientific article

Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JCM.00577-07
P932PMC publication ID1951238
P698PubMed publication ID17581934
P5875ResearchGate publication ID6255211

P50authorJohan WestinQ87926714
Magnus LindhQ87976200
Gunnar NorkransQ114372193
Rune WejstålQ114431759
Martin LaggingQ42980463
Kristoffer HellstrandQ61090166
P2093author name stringThomas Wahlberg
Birgitta Arnholm
Erik Alestig
Anders Eilard
P2860cites workHepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyQ27860724
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionQ27860901
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialQ27860949
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseQ29547886
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virusQ42983656
Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfaQ42987319
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.Q42994214
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological responseQ42994528
Genotyping of hepatitis C virus by Taqman real-time PCR.Q42995129
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaQ42996604
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C.Q42997337
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinQ42999474
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapyQ42999651
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.Q43001787
Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical modelQ43029666
How can mathematics help us understand HCV?Q43031038
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot studyQ43035085
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirinQ43037216
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Q43046858
Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivoQ43046883
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferonQ43048289
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapyQ43049563
Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapyQ45738503
First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.Q50575468
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinQ50578652
Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis CQ59284370
NIH Consensus Statement on Management of Hepatitis C: 2002Q75442808
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectHepatitis C virusQ708693
chronic hepatitis CQ55779873
chronic hepatitisQ62019625
P304page(s)2439-2445
P577publication date2007-06-20
P1433published inJournal of Clinical MicrobiologyQ4041880
P1476titleResponse prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection
P478volume45

Reverse relations

cites work (P2860)
Q35037574Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
Q41687110Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C.
Q42271105Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
Q26801602HCV Kinetic Models and Their Implications in Drug Development
Q37060801Hepatitis C Viral Kinetics in Special Populations
Q42997280Hepatitis C treatment response kinetics and impact of baseline predictors
Q43037898IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Q33987120Ribavirin improves early responses to peginterferon through improved interferon signaling
Q34493348S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders
Q42981009The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin
Q39649542Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment.

Search more.